NASDAQ: LUCY
Innovative Eyewear Inc Stock

$5.08+0.23 (+4.74%)
Updated Feb 10, 2025
LUCY Price
$5.08
Fair Value Price
N/A
Market Cap
$12.41M
52 Week Low
$3.26
52 Week High
$27.20
P/E
-0.53x
P/B
1.14x
P/S
9.29x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.56M
Earnings
-$8.03M
Gross Margin
-3.8%
Operating Margin
-514.51%
Profit Margin
-514.5%
Debt to Equity
0.06
Operating Cash Flow
-$6M
Beta
1.14
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

LUCY Overview

Innovative Eyewear, Inc. develops and sells smart eyeglasses and sunglasses. The company's flagship product is Lucyd Lyte glasses that enable the wearer to listen to music, take and make calls, and use voice assistants to perform various smartphone tasks hands-free. It also offers Vyrb, a social media application that enables the user to receive and send posts through Lucyd Lyte smart glasses with voice. The company sells its products through various e-commerce and retail distribution channels. Innovative Eyewear, Inc. has a partnership with Lucyd. The company was founded in 2019 and is headquartered in North Miami, Florida. Innovative Eyewear, Inc. operates as a subsidiary of Lucyd Ltd.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine LUCY's potential to beat the market

CHold
  • Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More

Zen Rating Component Grades

F
Value
C
Growth
C
Momentum
A
Sentiment
C
Safety
F
Financials
D
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Medical

Industry Rating
A
LUCY
Ranked
#43 of 49

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
$8.12A
$33.25A
$4.65A
View Top Medical Stocks

Be the first to know about important LUCY news, forecast changes, insider trades & much more!

LUCY News

Overview

Due Diligence Score

Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LUCY scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

LUCY is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
LUCY is good value based on its book value relative to its share price (1.14x), compared to the US Medical Instruments & Supplies industry average (4.11x)
P/B vs Industry Valuation
LUCY is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more LUCY due diligence checks available for Premium users.

Valuation

LUCY price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-0.53x
Industry
40.12x
Market
31x

LUCY price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
1.14x
Industry
4.11x
LUCY is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

LUCY's financial health

Profit margin

Revenue
$253.6k
Net Income
-$1.7M
Profit Margin
-678.5%
LUCY's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
LUCY's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$11.6M
Liabilities
$665.9k
Debt to equity
0.06
LUCY's short-term assets ($10.99M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LUCY's short-term assets ($10.99M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LUCY's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$1.4M
Investing
-$5.0M
Financing
$5.0M
LUCY's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

LUCY vs Medical Stocks

TickerZen RatingMarket Cap1d %P/EP/B
LUCYC$12.41M+4.74%-0.53x1.14x
EKSOD$12.65M+9.52%-0.88x0.85x
POAI$9.53M-1.38%-0.47x4.85x
BNGOF$8.87M-10.62%-0.04x0.18x
MHUA$8.28M+5.17%0.89x0.06x

Innovative Eyewear Stock FAQ

What is Innovative Eyewear's quote symbol?

(NASDAQ: LUCY) Innovative Eyewear trades on the NASDAQ under the ticker symbol LUCY. Innovative Eyewear stock quotes can also be displayed as NASDAQ: LUCY.

If you're new to stock investing, here's how to buy Innovative Eyewear stock.

What is the 52 week high and low for Innovative Eyewear (NASDAQ: LUCY)?

(NASDAQ: LUCY) Innovative Eyewear's 52-week high was $27.20, and its 52-week low was $3.26. It is currently -81.32% from its 52-week high and 55.83% from its 52-week low.

How much is Innovative Eyewear stock worth today?

(NASDAQ: LUCY) Innovative Eyewear currently has 2,442,248 outstanding shares. With Innovative Eyewear stock trading at $5.08 per share, the total value of Innovative Eyewear stock (market capitalization) is $12.41M.

Innovative Eyewear stock was originally listed at a price of $117.80 in Aug 15, 2022. If you had invested in Innovative Eyewear stock at $117.80, your return over the last 2 years would have been -95.69%, for an annualized return of -79.23% (not including any dividends or dividend reinvestments).

How much is Innovative Eyewear's stock price per share?

(NASDAQ: LUCY) Innovative Eyewear stock price per share is $5.08 today (as of Feb 10, 2025).

What is Innovative Eyewear's Market Cap?

(NASDAQ: LUCY) Innovative Eyewear's market cap is $12.41M, as of Feb 11, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Innovative Eyewear's market cap is calculated by multiplying LUCY's current stock price of $5.08 by LUCY's total outstanding shares of 2,442,248.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.